FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance …
6 days ago · Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab …
BIOGEN AND EISAI EXPAND EXISTING COLLABORATION …
Oct 23, 2017 · Under the terms of the agreement Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen's investigational anti-amyloid beta (Aβ) antibody for patients …
Biogen and Eisai amend collaboration agreements on Alzheimer’s …
Mar 15, 2022 · CAMBRIDGE, Mass., and TOKYO, March 14, 2022: Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today that the companies have amended their …
Biogen and Eisai Expand Existing Collaboration Agreement to …
Under the terms of the agreement Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’s investigational anti-amyloid beta (Aβ) antibody for patients with …
Eisai and Biogen shared LEQEMBI study results at AAIC 2024 | Eisai …
Jul 30, 2024 · Eisai and Biogen presented LEQEMBI findings from the Clarity AD Phase 3 study, showing significant reductions in cognitive decline and functional improvements.
New Clinical Data Demonstrates Three Years of ... - Eisai Co., Ltd.
Jul 31, 2024 · Dual-acting lecanemab is the only early AD treatment widely available to support neuronal function by clearing the highly toxic protofibrils that continue to cause neuronal injury …
Release Details - investors.biogen.com
1 day ago · Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab …
Eisai Newsroom - Press Releases
CAMBRIDGE, Mass., and TOKYO, March 14, 2022: Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today that the companies have amended their existing …
US FDA OKs monthly maintenance dosing for Eisai/Biogen's …
5 days ago · Jan 27 (Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai (4523.T), opens new tab and partner Biogen's (BIIB.O), …
Biogen, Eisai Alzheimer’s drug review delayed in EU - MSN
Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission …